Report Library
View More
Non-Small Cell Lung Cancer (NSCLC) ...
May 9, 2024
Renal Cell Carcinoma (RCC) KOL Inte...
May 7, 2024
Renal Cell Carcinoma (RCC) KOL Inte...
May 6, 2024
Renal Cell Carcinoma (RCC) KOL Inte...
May 3, 2024
Melanoma KOL Interview - US, Midwes...
April 30, 2024
Datamonitor Healthcare Infectious D...
April 29, 2024
Datamonitor Healthcare CV&Met Disea...
April 29, 2024
Datamonitor Healthcare I&I: Axial S...
April 29, 2024
Datamonitor Healthcare Infectious D...
April 29, 2024
Melanoma KOL Interview - Germany
April 26, 2024
Impact Events
More| Date | Lead Company | Event | Type | Approval Change | Approval Likelihood |
|---|---|---|---|---|---|
| 6/2/24 | Kelun Pharmaceutical (002422) | Sacituzumab Tirumotecan for Triple-Negative Breast Cancer (TNBC) | Subscribers Only | Subscribers Only | Subscribers Only |
| 6/2/24 | Daiichi Sankyo (4568) | Enhertu for HR+/HER2- Breast Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
| 6/2/24 | AbbVie (ABBV) | Telisotuzumab Vedotin for Non-Small Cell Lung Cancer (NSCLC) | Subscribers Only | Subscribers Only | Subscribers Only |
| 6/2/24 | Bristol Myers Squibb (BMY) | Opdivo for Melanoma | Subscribers Only | Subscribers Only | Subscribers Only |
| 6/2/24 | CG Oncology (CGON) | CG0070 for Bladder Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
More| Expected Date Range | Lead Company | Drug | Expected Catalyst |
|---|---|---|---|
| 03/19/24 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 04/09/24 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 04/15/24 | Subscribers Only | Subscribers Only | Partnership - Acquisition Completion |
| 04/15/24 | Subscribers Only | Subscribers Only | Partnership - Acquisition Completion |
| 04/18/24 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |